Indian Journal of Pharmaceutical Education and Research logo
Submit
Indian Journal of Pharmaceutical Education and ResearchAn Official Publication of Association of Pharmaceutical Teachers of India (APTI)
Article

In vitro Evaluation of the Antihyperlipidemic and Antioxidant Potential of Ethanolic Leaf Extract of Anisomeles malabarica (L.)

1, 1, 2

  1. 1Department of Pharmacology, The Erode College of Pharmacy, The Tamil Nadu Dr. M.G.R. Medical University, Erode, Tamil Nadu, INDIA.
  2. 2Department of Pharmacology, The Erode College of Pharmacy, The Tamil Nadu Dr. MGR Medical University, Erode, Nadu, Tamil INDIA.

CORRESPONDENCE

In Press · pp. · 2026 · DOI: 10.5530/ijper.20270114

ABSTRACT

Background: Hyperlipidemia and oxidative stress are closely linked to atherosclerosis and cardiovascular complications. Plant-derived phenolic compounds, flavonoids, alkaloids and saponins are widely investigated as sources of antioxidant and lipid-modulating activity.Objectives: To evaluate the preliminary in vitro antioxidant activity and 3-hydroxy-3methylglutaryl-coenzyme A reductase-related inhibitory potential of the ethanolic leaf extract of Anisomeles malabarica (AMLE).Materials and Methods: Leaves of Anisomeles malabarica were collected, authenticated, shade-dried, powdered and extracted with ethanol using a Soxhlet apparatus. The extract underwent qualitative phytochemical screening, nitric oxide scavenging and hydroxyl radical scavenging assays. 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related inhibitory activity was examined at 25, 50 and 100 µg/mL. IC50 values for the antioxidant assays were estimated by linear interpolation between concentrations bracketing 50% inhibition.Results: The ethanolic extract yield was 33.33% w/w. Qualitative screening indicated alkaloids, flavonoids, glycosides, saponins and tannins. AMLE showed concentration-dependent nitric oxide scavenging (IC50, 1537.47 µg/mL) and hydroxyl radical scavenging (IC50, 1303.17 µg/mL). The corresponding reference values were 440.72 µg/mL for the nitric oxide assay reference standard and 274.22 µg/mL for gallic acid in the hydroxyl radical assay. In the 3-hydroxy-3-methylglutarylcoenzyme A reductase-related assay, reported inhibition was 55.95%, 74.78% and 83.29% at 25, 50 and 100 µg/mL, respectively; interpretation remains preliminary pending assay validation and statin-control confirmation.Conclusion: AMLE demonstrated concentration-dependent in vitro radical-scavenging activity and a concentration-related response in the reported 3-hydroxy-3methylglutaryl-coenzyme A reductase-related assay. The antioxidant potency was substantially lower than the reference standards. These findings constitute preliminary in vitro evidence only and do not establish therapeutic antihyperlipidemic efficacy. Validated enzyme assays with a statin positive control, replicated measurements with statistical analysis, quantitative phytochemical characterization, in vivo evaluation and toxicity studies are required.

KEYWORDS

0% READ

FULL TEXT

INTRODUCTION

Hyperlipidemia is a major modifiable risk factor for atherosclerosis and cardiovascular disease.1–6 Elevated total cholesterol, triglycerides and low-density lipoprotein cholesterol, together with reduced high-density lipoprotein cholesterol, contribute to vascular lipid deposition and endothelial dysfunction.7–14 Oxidative stress further accelerates lipid peroxidation and oxidative modification of lipoproteins, thereby increasing the risk sions, wounds and gastrointestinal disorders.45–47 Previous studies family Lamiaceae. In traditional systems of medicine, its leaves and other parts have been used for fever, inflammation, convulsions, wounds and gastrointestinal disorders.45–47 Previous studies have reported antioxidant, anti-inflammatory, antibacterial and related pharmacological activities of the plant.45–48 Despite its traditional relevance, the specific effect of A. malabarica leaf extract on 3-hydroxy-3-methylglutaryl-coenzyme A reductase has received little attention in the plant-specific literature cited here.47,48 Previous reports have primarily described antioxidant, anti-inflammatory, antibacterial, anticonvulsant and other pharmacological activities.45–48 The novelty of the present study is therefore the extension of in vitro screening to an 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related endpoint, a cholesterol-biosynthesis target, while simultaneously comparing antioxidant activity in the same ethanolic leaf extract. Because the enzyme-assay validation details and statin positivecontrol data were not available in the supplied study records, the 3-hydroxy-3-methylglutaryl-coenzyme A finding is interpreted as exploratory rather than as proof of a therapeutic lipid-lowering effect.

Synthetic lipid-lowering drugs are effective; however, long-term therapy may be associated with adverse effects, variable patient adherence and cost-related limitations.5,6,22–29 Experimental and clinical studies of plant extracts and phytochemicals, including and Terminalia arjuna, have reported antioxidant or lipid-modulating effects.30–35 These observations support continued investigation of plant-derived compounds as potential sources

MATERIALS AND METHODS

Plant material and authentication

Fresh, disease-free leaves of Anisomeles malabarica (L.) were collected from Veppampalayam, Erode District, Tamil Nadu, India. The plant material was authenticated by Dr. M. U. Sharief, Scientist F and Head of Office, Botanical Survey of India, Southern Regional Centre, T.N.A.U. Campus, Coimbatore, Tamil Nadu. The authentication reference number was BSI/SRC/5/23/2024-25/TECH./550.

Preparation of ethanolic leaf extract

The collected leaves were washed, shade-dried at room temperature (25-27ºC) and mechanically powdered. A total of 120 g of dried leaf powder was extracted with 1000 mL ethanol in a Soxhlet apparatus at 40-45ºC for approximately 70 hr. The extract was concentrated by distillation and stored in an airtight container until analysis. Percentage yield was calculated as: percentage yield = (weight of dried extract / weight of dried plant material) × 100.

Preliminary phytochemical screening

The ethanolic leaf extract was screened qualitatively for alkaloids, flavonoids, tannins, saponins and glycosides using standard phytochemical tests.42,50–53 Wagner's test was used for alkaloids, the ferric chloride test for flavonoids and tannins, the froth test for saponins and Legal's test for glycosides. No quantitative Total Flavonoid Content (TFC), Total Phenolic Content (TPC), or other quantitative phytochemical measurement was available in the supplied experimental dataset; therefore, no numerical TFC/TPC claim is made in this revision.

Nitric oxide scavenging assay

Nitric oxide scavenging activity was determined using sodium nitroprusside and Griess reagent according to the established assay principle.54,55 AMLE was evaluated at 125, 250, 500, 1000 and 2000 µg/mL. The same concentration series was used for the laboratory reference standard. After incubation with sodium nitroprusside, the reaction mixture was treated with Griess reagent, absorbance was read at 546 nm, and percentage inhibition was calculated relative to the assay control.

Hydroxyl radical scavenging assay

Hydroxyl radical scavenging activity was evaluated using a standard spectrophotometric method with gallic acid as the reference standard.56,57 AMLE and gallic acid were tested at 125, 250, 500, 1000 and 2000 µg/mL. Percentage inhibition was calculated relative to the control.

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory assay

3-hydroxy-3-methylglutaryl-coenzyme A inhibitory assay

The supplied study records describe a 3-hydroxy-3-methylglutarylcoenzyme A reductase-related inhibitory assay in which AMLE was tested at concentrations of 25, 50 and 100 µg/mL, and absorbance was recorded at 540 nm. However, the records do not specify whether the procedure was a direct enzyme-activity assay, a 3-hydroxy-3-methylglutaryl-coenzyme A/mevalonate ratio method, or a commercial kit-based assay, and they do not document the enzyme source, manufacturer/catalogue number, reagent concentrations, incubation conditions, or validated percentage-inhibition formula. These details must be verified from the laboratory record before resubmission.

Statistical analysis

Replicate-level raw observations were not included in the supplied manuscript or supporting material, so the number of independent replicates, SD/SEM values and inferential statistics cannot be reconstructed without fabricating data. Before resubmission, the authors should insert the verified replicate number (n), report each result as mean±SD (or mean±SEM, if that was prospectively used), and analyze concentration-dependent comparisons using an appropriate model (for example, oneway ANOVA with a prespecified multiple-comparison procedure, or two-way ANOVA where treatment and concentration are both factors), with p<0.05 as the significance threshold. IC50 values in this revision were estimated from the reported concentration-response values by linear interpolation between the two concentrations bracketing 50% inhibition: IC50 = C1 + [(50 -I1)/ (I2 -I1)] × (C2 -C1), where C1 and C2 are the bracketing concentrations and I1 and I2 are their corresponding percentage inhibitions.

Ethics statement

Ethics approval was not applicable because the study involved authenticated plant material and in vitro assays only; no human participants, human samples or experimental animals were used.

The experimental workflow is summarized in Figure 2.

Table 1 Extractive yield of the ethanolic leaf extract of A. malabarica.
ParameterValue
Driedleafpowderused120g
SolventEthanol
Solventvolume1000mL
ExtractionmethodSoxhletextraction
Driedextractobtained40g
Percentageyield33.33%w/w
Figure 1 AMLE preparation and the qualitative phytochemical, antioxidant and 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related screening workflow.
Figure 2 Experimental workflow from authenticated plant material through ethanolic extraction, antioxidant assays and exploratory 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related evaluation.

RESULTS

Extractive yield

Extraction of 120 g dried leaf powder with ethanol yielded 40 g dried extract, corresponding to 33.33% w/w. The extraction details are summarized in Table 1.

Phytochemical screening

Preliminary phytochemical screening indicated the presence of alkaloids, flavonoids, glycosides, saponins and tannins in AMLE (Table 2). These constituents are consistent with the reported pharmacological importance of plant secondary metabolites and flavonoid-rich extracts. 42,52,53 5.

available in the supplied dataset.

Nitric oxide scavenging activity

AMLE showed concentration-dependent nitric oxide scavenging activity (Table 3 and Figure 3). At 2000 µg/mL, AMLE produced 56.48% inhibition, whereas the reference standard produced 81.77% inhibition. Using linear interpolation between the concentrations bracketing 50% inhibition, the estimated IC50 was 1537.47 µg/mL for AMLE and 440.72 µg/mL for the reference standard. Thus, the AMLE IC50 was approximately 3.49-fold higher, indicating clearly lower potency than the reference standard.

Hydroxyl radical scavenging activity

AMLE demonstrated concentration-dependent hydroxyl radical scavenging activity (Table 4 and Figure 4). At 2000 µg/mL, AMLE produced 57.47% inhibition, while gallic acid produced 88.41% inhibition. Linear interpolation gave IC50 estimates of 1303.17 µg/mL for AMLE and 274.22 µg/mL for gallic acid. The AMLE IC50 was therefore approximately 4.75-fold higher than that of gallic acid, demonstrating weaker radical-scavenging potency.

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity

AMLE showed a concentration-related response in the reported

3-hydroxy-3-methylglutaryl-coenzyme A reductase-related assay

3-hydroxy-3-methylglutaryl-coenzyme A inhibitoryactivity

(Table 5 and Figure 5). The reported percentage inhibition increased from 55.95% at 25 µg/mL to 83.29% at 100 µg/mL. Because the calculation formula, replicate-level observations and a statin positive control were not supplied, these values are retained as reported and are interpreted as exploratory rather than as validated enzyme-inhibition estimates.

Table 2 Qualitative phytochemical screening of AMLE.
Sl. No.Phytochemical constituentResult
1.AlkaloidsPresent
2.FlavonoidsPresent
3.GlycosidesPresent
4.SaponinsPresent
5.TanninsPresent
Table 3 Nitric oxide scavenging activity of AMLE and the reference standard.
Concentration (µg/mL)Reference standard inhibition(%)AMLEinhibition (%)
12529.2912.75
25040.6722.66
50052.9033.40
100067.6542.47
200081.7756.48
Table 4 Hydroxyl radical scavenging activity of AMLE and gallic acid.
Concentration (µg/mL)Gallicacid inhibition(%)AMLEinhibition (%)
12525.4911.78
25048.4821.09
50064.1733.22
100074.6946.75
200088.4157.47
Table 5 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity of AMLE.
Concentrationof AMLE(µg/mL)Absorbanceat 540nmReported inhibition(%)
Blank(None; valuesnoted asreported- onlypending validation)0.51820.00
250.372555.95
500.301974.78
1000.260683.29
Figure 3 Nitric oxide scavenging concentration-response curves for AMLE and the laboratory reference standard. The horizontal dashed line indicates 50% inhibition.
Figure 4 Hydroxyl radical scavenging concentration-response curves for AMLE and gallic acid. The horizontal dashed line indicates 50% inhibition.

DISCUSSION

The present study indicates that the ethanolic leaf extract of Anisomeles malabarica contains alkaloids, flavonoids, glycosides, saponins and tannins.45–48 These constituents are frequently associated with antioxidant and lipid-modulating effects.42,52,53,58–60 Flavonoids and tannins may contribute to free-radical scavenging through hydrogen donation, metal chelation and interruption of oxidative chain reactions, whereas saponins may influence lipid metabolism through interactions with bile acids and intestinal lipid absorption.52,53,58–60 The nitric oxide and hydroxyl radical assays showed concentration-dependent activity, but the extract was substantially less potent than the corresponding reference standards.54–57 At the highest tested concentration (2000 µg/mL), AMLE inhibited nitric oxide and hydroxyl radical readouts by only 56.48% and 57.47%, respectively, compared with 81.77% for the nitric oxide reference standard and 88.41% for gallic acid. The interpolated IC50 values for AMLE were approximately 3.49-fold and 4.75-fold higher than the respective standards. These differences should be viewed as a limitation rather than evidence of strong antioxidant potency. The data support only modest in vitro radical-scavenging activity over the tested range.

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related result is the most potentially novel aspect of the study because prior plant-specific reports cited here focused largely on other pharmacological effects. 45-48 3-hydroxy-3-methylglutarylcoenzyme A reductase is a central regulatory enzyme in cholesterol biosynthesis and a pharmacological target of statins.5–822–25 Nevertheless, the present dataset does not establish validated enzyme inhibition: a statin positive control was not documented, the assay principle and percentage-inhibition calculation require confirmation, and no replicate-level variability was supplied.

Accordingly, the apparent concentration-related response should be treated as a hypothesis-generating observation that requires confirmation in a validated 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme-activity assay.

The study has several limitations. First, the phytochemical analysis was qualitative; quantitative TFC/TPC measurements and chromatographic characterization of the extract were not available. Second, replicate-level observations, variability estimates and inferential statistical results were not supplied. Third, the identity of the nitric oxide assay reference standard was not documented in the provided records. Fourth, the 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related assay lacks a documented statin positive control and complete validation information. Finally, all experiments were in vitro. Therefore, the present findings should be regarded as preliminary biochemical screening and should not be interpreted as evidence of clinical or therapeutic antihyperlipidemic efficacy.

Figure 5 Concentration-related 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related response reported for AMLE.A statin positive-control curve must be added when the corresponding laboratory data are provided.

CONCLUSION

The ethanolic leaf extract of Anisomeles malabarica contained alkaloids, flavonoids, glycosides, saponins and tannins on qualitative screening and showed concentration-dependent activity in nitric oxide and hydroxyl radical scavenging assays.45–4852–57 However, its antioxidant potency was lower than the reference standards. The extract also showed a concentration-related response in the reported 3-hydroxy-3-methylglutaryl-coenzyme A reductase-related assay, but the absence of documented assay-validation details, replicate statistics and a statin positive control precludes a therapeutic inference. The findings therefore provide preliminary in vitro evidence that warrants confirmation through validated enzyme assays, quantitative phytochemical characterization, replicated statistical analysis, in vivo antihyperlipidemic models and toxicity assessment.

Acknowledgement

The authors acknowledge the Botanical Survey of India, Southern Regional Centre, Coimbatore, for authentication of the plant material.

Funding

Nil.

Conflict of Interest

AMLE: Ethanolic leaf extract of A. malabarica; Enzyme-linked immunosorbent assay; HMG-CoA: 3-Hydroxy-3-methylglutaryl-coenzyme A; IC₅₀: Half-maximal inhibitory concentration.

The authors declare that there is no conflict of interest.

Author Contributions

All authors contributed to the study conception, experimental work, data analysis, manuscript preparation, review, and approval of the final manuscript.

REFERENCES

As published

Showing references and in-text citations exactly as published.

  1. 1.Libby, P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-74. https://doi.org/10.1038/nature01323CrossrefGOOGLE SCHOLAR
  2. 2.Ross, R. Atherosclerosis -An Inflammatory Disease. New England Journal of Medicine 1999;340(2):115-26. https://doi.org/10.1056/NEJM199901143400207CrossrefGOOGLE SCHOLAR
  3. 3.Hansson, G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95. https://doi.org/10.1056/NEJMra043430CrossrefGOOGLE SCHOLAR
  4. 4.Lusis, A., Atherosclerosis. Atherosclerosis. Nature 2000;407(6801):233-41. https://doi.org/10.1038/35025203CrossrefGOOGLE SCHOLAR
  5. 5.Grundy, S., Stone, N., Bailey, A. AHA/ACC guideline on the management of blood cholesterol. J Am Coll Cardiol 2019;73(24):e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003CrossrefGOOGLE SCHOLAR
  6. 6.Ference, B., Ginsberg, H., Graham, I. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J 2017;38(32):2459-72. https://doi.org/10.1093/eurheartj/ehx144CrossrefGOOGLE SCHOLAR
  7. 7.Brown, M., Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232(4746):34-47. https://doi.org/10.1126/science.3513311CrossrefGOOGLE SCHOLAR
  8. 8.Goldstein, J., Brown, M. Regulation of the mevalonate pathway. Nature 1990;343(6257):425-30. https://doi.org/10.1038/343425a0CrossrefGOOGLE SCHOLAR
  9. 9.Maxfield, F., Tabas, I. Role of cholesterol and lipid organization in disease. Nature 2005;438(7068):612-21. https://doi.org/10.1038/nature04399CrossrefGOOGLE SCHOLAR
  10. 10.Rader, D., Alexander, E., Weibel, G., Billheimer, J., Rothblat, G. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl):S189-S194. https://doi.org/10.1194/jlr.R800088-JLR200CrossrefGOOGLE SCHOLAR
  11. 11.Friedewald, W., Levy, R., Fredrickson, D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499CrossrefGOOGLE SCHOLAR
  12. 12.Miller, M., Stone, N., Ballantyne, C. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011;123(20):2292-333. https://doi.org/10.1161/CIR.0b013e3182160726CrossrefGOOGLE SCHOLAR
  13. 13.Bhatt, D., Steg, P., Miller, M. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380(1):11-22. https://doi.org/10.1056/NEJMoa1812792CrossrefGOOGLE SCHOLAR
  14. 14.Nordestgaard, B., Varbo, A. Triglycerides and cardiovascular disease. Lancet 2014;384(9943):626-35. https://doi.org/10.1016/S0140-6736(14)61177-6CrossrefGOOGLE SCHOLAR
  15. 15.Steinberg, D., Parthasarathy, S., Carew, T., Khoo, J., Witztum, J. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320(14):915-24. https://doi.org/10.1056/NEJM198904063201407CrossrefGOOGLE SCHOLAR
  16. 16.Valko, M., Leibfritz, D., Moncol, J., Cronin, M., Mazur, M., Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39(1):44-84. https://doi.org/10.1016/j.biocel.2006.07.001CrossrefGOOGLE SCHOLAR
  17. 17.Sies, H. Oxidative stress: A concept in redox biology and medicine. redox biol 2015;4:180-3. https://doi.org/10.1016/j.redox.2015.01.002CrossrefGOOGLE SCHOLAR
  18. 18.Pizzino, G., Irrera, N., Cucinotta, M. Oxidative stress: Harms and benefits for human health. Oxid Med Cell Longev 2017;2017(1):8416763. https://doi.org/10.1155/2017/8416763CrossrefGOOGLE SCHOLAR
  19. 19.Phaniendra, A., Jestadi, D., Periyasamy, L. Free radicals: Properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 2015;30(1):11-26. https://doi.org/10.1007/s12291-014-0446-0CrossrefGOOGLE SCHOLAR
  20. 20.Tangvarasittichai, S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015;6(3):456-80. https://doi.org/10.4239/wjd.v6.i3.456CrossrefGOOGLE SCHOLAR
  21. 21.Willcox, J., Ash, S., Catignani, G. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 2004;44(4):275-95. https://doi.org/10.1080/10408690490468489CrossrefGOOGLE SCHOLAR
  22. 22.Mach, F., Baigent, C., Catapano, A. ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111-88. https://doi.org/10.1093/eurheartj/ehz455CrossrefGOOGLE SCHOLAR
  23. 23.Catapano, A., Graham, I., De Backer, G. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37(39):2999-3058. https://doi.org/10.1093/eurheartj/ehw272CrossrefGOOGLE SCHOLAR
  24. 24.Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81. https://doi.org/10.1016/S0140-6736(10)61350-5CrossrefGOOGLE SCHOLAR
  25. 25.Baigent, C., Keech, A., Kearney, P. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78. https://doi.org/10.1016/S014CrossrefGOOGLE SCHOLAR
  26. 26.Cannon, C., Blazing, M., Giugliano, R. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372(25):2387-97. https://doi.org/10.1056/NEJMoa1410489CrossrefGOOGLE SCHOLAR
  27. 27.Sabatine, M., Giugliano, R., Keech, A. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376(18):1713-22. https://doi.org/10.1056/NEJMoa1615664CrossrefGOOGLE SCHOLAR
  28. 28.Schwartz, G., Steg, P., Szarek, M. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379(22):2097-107. https://doi.org/10.1056/NEJMoa1801174CrossrefGOOGLE SCHOLAR
  29. 29.Nissen, S., Lincoff, A., Brennan, D. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388(15):1353-64. https://doi.org/10.1056/NEJMoa2215024CrossrefGOOGLE SCHOLAR
  30. 30.Huang, S., Liu, H., Meng, N., Li, B., Wang, J. Hypolipidemic and antioxidant effects of *Malus toringoides* (Rehd.) Hughes leaves in high-fat-diet-induced hyperlipidemic rats. J Med Food 2017;20(3):258-64. https://doi.org/10.1089/jmf.2016.3778CrossrefGOOGLE SCHOLAR
  31. 31.Xiao, L., Lu, X., Yang, H., Lin, C., Li, L., Ni, C., Fang, Y., Mo, S., Zhan, R., Yan, P. The antioxidant and hypolipidemic effects of *Mesona chinensis* Benth extracts. Molecules 2022;27(11):3423. https://doi.org/10.3390/molecules27113423CrossrefGOOGLE SCHOLAR
  32. 32.Alkhudhayri, D., Osman, M., Alshammari, G., Al Maiman, S., Yahya, M. Moringa *peregrina* leaf extracts produce anti-obesity, hypoglycemic, anti-hyperlipidemic, and hepatoprotective effects on high-fat diet fed rats. Saudi J Biol Sci 2021;28(6):3333-42. https://doi.org/10.1016/j.sjbs.2021.02.078CrossrefGOOGLE SCHOLAR
  33. 33.Bais, S., Singh, G., Sharma, R. Antiobesity and hypolipidemic activity of *Moringa oleifera* leaves against high fat diet-induced obesity in rats. Adv Biol 2014;2014(1):162914. https://doi.org/10.1155/2014/162914CrossrefGOOGLE SCHOLAR
  34. 34.Sahebkar, A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr 2014;33(3):406-14. https://doi.org/10.1016/j.clnu.2013.07.005CrossrefGOOGLE SCHOLAR
  35. 35.Amalraj, A., Gopi, S. Medicinal properties of *Terminalia arjuna* (Roxb.) Wight & Arn.: A review. J Tradit Complement Med 2017;7(1):65-78. https://doi.org/10.1016/j.jtcme.2016.02.003CrossrefGOOGLE SCHOLAR
  36. 36.Newman, D., Cragg, G. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016;79(3):629-61. https://doi.org/10.1021/acs.jnatprod.5b01055CrossrefGOOGLE SCHOLAR
  37. 37.Atanasov, A., Waltenberger, B., Pferschy-Wenzig. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv 2015;33(8):1582-614. https://doi.org/10.1016/j.biotechadv.2015.08.001CrossrefGOOGLE SCHOLAR
  38. 38.Fabricant, D., Farnsworth, N. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001;109(Suppl 1):69-75. https://doi.org/10.1289/ehp.01109s169CrossrefGOOGLE SCHOLAR
  39. 39.Cragg, G., Newman, D. Natural products: A continuing source of novel drug leads. Bioorg Med Chem 2013;21(6):1345-59. https://doi.org/10.1016/j.bmc.2013.02.008CrossrefGOOGLE SCHOLAR
  40. 40.Pan, S., Zhou, S., Gao, S., Yu, Z., Zhang, S., Tang, M. New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. Evidence-Based Complementary and Alternative Medicine 2013;2013(1):1-25. https://doi.org/10.1155/2013/627375CrossrefGOOGLE SCHOLAR
  41. 41.Ekor, M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014;4:177. https://doi.org/10.3389/fphar.2013.00177CrossrefGOOGLE SCHOLAR
  42. 42.Wink, M. Modes of action of herbal medicines and plant secondary metabolites. Medicines (Basel) 2015;2(3):251-86. https://doi.org/10.3390/medicines2030251CrossrefGOOGLE SCHOLAR
  43. 43.Harvey, A. Natural products in drug discovery. Drug Discov Today 2008;13(19- 20):894-901. https://doi.org/10.1016/j.drudis.2008.07.004CrossrefGOOGLE SCHOLAR
  44. 44.Yuan, H., Ma, Q., Ye, L., Piao, G. The traditional medicine and modern medicine from natural products. Molecules 2016;21(5):559. https://doi.org/10.3390/molecules21050559CrossrefGOOGLE SCHOLAR
  45. 45.Choudhary, N., Bijjem, K., Kalia, A. Antiepileptic potential of flavonoids fraction from the leaves of *Anisomeles malabarica*. J Ethnopharmacol 2011;135(2):238-42. https://doi.org/10.1016/j.jep.2011.02.019CrossrefGOOGLE SCHOLAR
  46. 46.Singh, I., Singh, M., Singh, T. Anticonvulsant potential of *Anisomeles malabarica* leaves against experimentally induced convulsions in rats. Int J Green Pharm 2010;4(3):144-8. https://doi.org/10.4103/0973-8258.69182CrossrefGOOGLE SCHOLAR
  47. 47.Anandhan, R. A brief review on phytochemical constituents and pharmacological activities of *Anisomeles malabarica* (L.). Environ Ecol 2024;42(2):547-52. https://doi.org/10.60151/envec/RNSW4006CrossrefGOOGLE SCHOLAR
  48. 48.Jansi, P., Padua, J. Evaluation of *in vitro* antioxidant and anti-inflammatory activities of *Anisomeles malabarica* leaf extract. Res J Pharm Technol 2026;19(3):1295-300. https://doi.org/10.52711/0974-360X.2026.00185CrossrefGOOGLE SCHOLAR
  49. 49.Chaudhary, S., Sharma, K., Devi, S., Kar, A., Bhardwaj, P., Sharma, N. Evaluation of anti-HMG-CoA reductase potential and simultaneous determination of phenolic compounds in hydroalcoholic extract of *Ficus cunia* fruits by RP-HPLC. South African Journal of Botany 2023;155:27-34. https://doi.org/10.1016/j.sajb.2023.02.001CrossrefGOOGLE SCHOLAR
  50. 50.Singleton, V., Orthofer, R., Lamuela-Raventos, R. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol 1999;299:152-78. https://doi.org/10.1016/S0076-6879(99)99017-1CrossrefGOOGLE SCHOLAR
  51. 51.Sreevidya, N., Mehrotra, S. Spectrophotometric method for estimation of alkaloids precipitable with Dragendorff's reagent in plant materials. J AOAC Int 2003;86(6):1124-7. https://doi.org/10.1093/jaoac/86.6.1124CrossrefGOOGLE SCHOLAR
  52. 52.Panche, A., Diwan, A., Chandra, S. Flavonoids: An overview. J Nutr Sci 2016;5:e47. https://doi.org/10.1017/jns.2016.41CrossrefGOOGLE SCHOLAR
  53. 53.Kumar, S., Pandey, A. Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal 2013;2013(1):162750. https://doi.org/10.1155/2013/162750CrossrefGOOGLE SCHOLAR
  54. 54.Marcocci, L., Maguire, J., Droy-Lefaix, M., Packer, L. The nitric oxide-scavenging properties of *Ginkgo biloba* extract EGb 761. Biochem Biophys Res Commun 1994;201(2):748-55. https://doi.org/10.1006/bbrc.1994.1724CrossrefGOOGLE SCHOLAR
  55. 55.Prior, R., Wu, X., Schaich, K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem 2005;53(10):4290-302. https://doi.org/10.1021/jf0502698CrossrefGOOGLE SCHOLAR
  56. 56.Aruoma, O. Deoxyribose assay for detecting hydroxyl radicals. Methods Enzymol 1994;233:57-66. https://doi.org/10.1016/0076-6879(94)33006-8CrossrefGOOGLE SCHOLAR
  57. 57.Halliwell, B. Antioxidant characterization: Methodology and mechanism. Biochem Pharmacol 1995;49(10):1341-8. https://doi.org/10.1016/0006-2952(95)00088-HCrossrefGOOGLE SCHOLAR
  58. 58.Crozier, A., Jaganath, I., Clifford, M. Dietary phenolics: Chemistry, bioavailability and effects on health. Nat Prod Rep 2009;26(8):1001-43. https://doi.org/10.1039/B802662ACrossrefGOOGLE SCHOLAR
  59. 59.Manach, C., Scalbert, A., Morand, C., Remesy, C., Jimenez, L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004;79(5):727-47. https://doi.org/10.1093/ajcn/79.5.727CrossrefGOOGLE SCHOLAR
  60. 60.Middleton, E., Kandaswami, C., Theoharides, T. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52(4):673-751. https://doi.org/10.1124/pr.52.4.673CrossrefGOOGLE SCHOLAR

Cite this article

SELECT FORMAT

Sr, A. S., Athan, H., & Anandhi, M. (2026). In vitro Evaluation of the Antihyperlipidemic and Antioxidant Potential of Ethanolic Leaf Extract of Anisomeles malabarica (L.). Indian Journal of Pharmaceutical Education and Research, 0(0). https://doi.org/10.5530/ijper.20270114

Copyright and licence

© 2026 Author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0